HRP970567A2 - Nicotinic agents in addiction therapy - Google Patents

Nicotinic agents in addiction therapy

Info

Publication number
HRP970567A2
HRP970567A2 HR60/028,804A HRP970567A HRP970567A2 HR P970567 A2 HRP970567 A2 HR P970567A2 HR P970567 A HRP970567 A HR P970567A HR P970567 A2 HRP970567 A2 HR P970567A2
Authority
HR
Croatia
Prior art keywords
pyrido
hexahydro
methane
diazocin
boc
Prior art date
Application number
HR60/028,804A
Other languages
English (en)
Croatian (hr)
Inventor
Brian Thomas O'neill
Original Assignee
Brian Thomas O'neill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brian Thomas O'neill filed Critical Brian Thomas O'neill
Publication of HRP970567A2 publication Critical patent/HRP970567A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
HR60/028,804A 1996-10-30 1997-10-24 Nicotinic agents in addiction therapy HRP970567A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2880496P 1996-10-30 1996-10-30

Publications (1)

Publication Number Publication Date
HRP970567A2 true HRP970567A2 (en) 1998-10-31

Family

ID=21845528

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/028,804A HRP970567A2 (en) 1996-10-30 1997-10-24 Nicotinic agents in addiction therapy

Country Status (17)

Country Link
US (2) US6235734B1 (de)
EP (1) EP0937077B1 (de)
JP (2) JP3621707B2 (de)
AP (1) AP9701125A0 (de)
AR (1) AR008901A1 (de)
AT (1) ATE326468T1 (de)
AU (1) AU4394897A (de)
DE (1) DE69735891T2 (de)
ES (1) ES2264169T3 (de)
GT (1) GT199700115A (de)
HR (1) HRP970567A2 (de)
ID (1) ID18741A (de)
MA (1) MA26445A1 (de)
PA (1) PA8440201A1 (de)
TN (1) TNSN97168A1 (de)
WO (1) WO1998018798A1 (de)
ZA (1) ZA979706B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
ATE405574T1 (de) 2001-11-30 2008-09-15 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US8030300B2 (en) 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
ES2331245T3 (es) 2003-07-21 2009-12-28 Pfizer Products Inc. Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
US7135933B2 (en) * 2004-09-29 2006-11-14 Intelliserv, Inc. System for adjusting frequency of electrical output pulses derived from an oscillator
ATE395348T1 (de) * 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US20090318491A1 (en) * 2006-01-27 2009-12-24 Yale Univeristy Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
WO2007115092A2 (en) * 2006-03-29 2007-10-11 Georgetown University 10-substituted cytisine derivatives and methods of use thereof
US7404725B2 (en) * 2006-07-03 2008-07-29 Hall David R Wiper for tool string direct electrical connection
US8061443B2 (en) * 2008-04-24 2011-11-22 Schlumberger Technology Corporation Downhole sample rate system
CN106367478A (zh) 2009-12-22 2017-02-01 雅芳产品公司 桩蛋白刺激组合物及其化妆品用途
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
FR2992315B1 (fr) * 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN102952134B (zh) * 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
AU2017313390A1 (en) 2016-08-19 2019-03-07 The University Of Bristol Cytisine derivatives for the treatment of addiction
AU2018306520B2 (en) 2017-07-24 2022-07-21 Achieve Pharma Uk Limited Cytisine salts
DK4027815T5 (en) * 2019-09-12 2026-08-03 Achieve Life Sciences Inc Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59500217A (ja) 1982-02-22 1984-02-16 ベロルススキ− ナウチノ− イスレドワ−チエルスキ− サニタルノ− ギギエニチエスキ− インスチツ−ト 抗ニコチン効果を有する製剤およびその製造法
US4835162A (en) * 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
TW261531B (de) * 1993-10-28 1995-11-01 Dynagen Inc
EP0853621A1 (de) * 1995-09-22 1998-07-22 Novo Nordisk A/S Neue substituierte azazyklische oder azabizyklische verbindungen

Also Published As

Publication number Publication date
WO1998018798A1 (en) 1998-05-07
AU4394897A (en) 1998-05-22
EP0937077A1 (de) 1999-08-25
US20030065173A1 (en) 2003-04-03
ID18741A (id) 1998-05-07
GT199700115A (es) 1999-04-20
DE69735891T2 (de) 2006-12-14
JP3621707B2 (ja) 2005-02-16
AP9701125A0 (en) 1997-10-31
DE69735891D1 (de) 2006-06-22
JP2000505809A (ja) 2000-05-16
TNSN97168A1 (fr) 2005-03-15
ZA979706B (en) 1999-04-29
EP0937077B1 (de) 2006-05-17
PA8440201A1 (es) 2000-05-24
MA26445A1 (fr) 2004-12-20
AR008901A1 (es) 2000-02-23
JP2005060403A (ja) 2005-03-10
ATE326468T1 (de) 2006-06-15
US6235734B1 (en) 2001-05-22
US6630467B2 (en) 2003-10-07
ES2264169T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
US6235734B1 (en) Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
KR102114536B1 (ko) RORγ 조정제로서의 트리시클릭 술폰
JP2656700B2 (ja) 置換キヌクリジン誘導体
AU744259B2 (en) Analogs of cocaine
EP0610793A1 (de) Tetracyclische Morpholin-Derivate und ihre Verwendung als Analgetika
HUT65771A (en) Process for producing substituted 3-amino-quinuclidine derivatives and pharmaceutical compositions containing them
TW200902518A (en) Substituted heterocyclic derivatives and their pharmaceutical use and compositions
TW201036974A (en) Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
AU2024219951A1 (en) Dopamine D3 receptor selective antagonists/partial agonists and uses thereof
US6143761A (en) 2,3-dihydrofuro [3,2-β]pyridin, preparation and application thereof in therapy
US8445684B2 (en) Nicotinic acetylcholine receptor ligands and the uses thereof
CN110167930A (zh) RORγ调节剂
TW202208374A (zh) 經取代三環醯胺類、其類似物及使用其之方法
CN110278711A (zh) 作为RORγ调节剂的三环砜
HUT58095A (en) Process for producing benzo(d,e)-isoquinolin-1-one derivatives and pharmaceutical compositions comprising same
JP2008523045A (ja) ニューロンニコチン性アセチルコリン特異的受容体部位に結合し、コリン作動性機能の調節および習慣性障害の治療に有用である1,2,3,3a,8,8a−ヘキサヒドロ−2,7a−ジアダ−シクロペンタ[a]インデン−7−オン誘導体
JP2719063B2 (ja) 置換3−アミノキヌクリジンp物質拮抗剤
CA2146000A1 (en) 3,3-disubstituted tri-and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
KR100222238B1 (ko) 스피로 교상 및 비교상 헤테로고리 화합물
Huang The synthesis of 5-substituted E ring, and B/E ring analogues of methyllycaconitine (MLA)
US20130184313A1 (en) Nicotinic acetylcholine receptor ligands and the uses thereof
TW200914010A (en) Novel compounds

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 19981024

Year of fee payment: 1

A1OB Publication of a patent application
ODBI Application refused